Skip to main content
Premium Trial:

Request an Annual Quote

Armed Forces to Use Calibrant's Gemini for Biomarker Research

NEW YORK (GenomeWeb News) – The Armed Forces Institute of Pathology will use Calibrant Biosystems’ Gemini proteomics platform to validate biomarkers for brain cancer and to discover other predictive markers, the company said today.
Under a Cooperative Research and Development Agreement, AFIP, which is part of the US Department of Defense, will produce custom tissue microarrays in agreement with Calibrant’s specifications. The collaboration will focus initially on brain cancer with the ultimate goal of identifying predictive markers for personalized medicine, said Calibrant.
The Gemini platform is compatible with fresh and formalin-fixed archival tissues, allowing users to map protein networks between different cell types within one tissue section.
Michael Salgaller, COO of Gaithersburg, Md.-based Calibrant, said in a statement that the AFIP partnership is “an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples.”
Financial terms of the agreement were not released.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.